Publication details
Studie IMPROVE-IT změnila strategii hypolipidemické léčby
Title in English | IMPROVE-IT has changed the strategy ofhypolipidemic treatment |
---|---|
Authors | |
Year of publication | 2015 |
Type | Article in Periodical |
Magazine / Source | Remedia |
MU Faculty or unit | |
Citation | |
Field | Cardiovascular diseases incl. cardiosurgery |
Keywords | acute coronary syndrome; LDL-cholesterol; combination therapy; ezetimibe |
Description | The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT; randomized double blind clinical trial) is evaluating the potential benefit - reduction in major cardiovascular (CV) events - of the addition ofezetimibe versus placebo to simvastatin 40 mg/d (or 80 mg/d) in patients who present with acute coronary syndromes and have low-density lipoprotein cholesterol (LDL-C) < 125 mg/dL. The simvastatin monotherapy arm's LDL-C target was <70 mg/dL, the comparison arm was simvastatin + ezetimibe. Ezetimibe was assumed to further lower LDL-C by 15 mg/dL and produce an estimated -8% to 9% treatment effect. The primary composite end point comprised CV death, nonfatal myo-cardial infarction (Ml), nonfatal stroke, rehospitalization for unstable angina (UA), and coronary revascularization (> 30 days postrandomization). The target number of events was 5,250. |